Skip to main content
Top
Published in: Annals of Hematology 9/2018

01-09-2018 | Original Article

− 174 G>C IL-6 polymorphism and primary iron overload in male patients

Authors: Walter F. Tetzlaff, Tomás Meroño, Eliana E. Botta, Maximiliano E. Martín, Patricia B. Sorroche, Laura E. Boero, Marcelo Castro, Gustavo D. Frechtel, Jorge Rey, Jorge Daruich, Gloria E. Cerrone, Fernando Brites

Published in: Annals of Hematology | Issue 9/2018

Login to get access

Abstract

Primary iron overload (IO) is commonly associated with mutations in the hereditary hemochromatosis gene (HFE). Nonetheless, other genetic variants may influence the development of IO beyond HFE mutations. There is a single nucleotide polymorphism (SNP) at − 174 G>C of the interleukin (IL)-6 gene which might be associated with primary IO. Our aim was to study the association between the SNP − 174 G>C gene promoter of IL-6 and primary IO in middle-aged male patients. We studied 37 men with primary IO diagnosed by liver histology. Controls were age-matched male volunteers (n = 37). HFE mutations and the SNP − 174 G>C gene promoter of IL-6 were evaluated by PCR-RFLP. Logistic regression was used to evaluate the association between primary IO and SNP − 174 G>C gene promoter of IL-6. Patients and control subjects were in Hardy-Weinberg equilibrium for the SNP − 174 G>C gene promoter of IL-6 (p = 0.17). Significantly different genotype frequencies were observed between patients (43% CC, 43% CG, and 14% GG) and control subjects (10% CC, 41% CG, and 49% GG) (OR = 4.09, 95% CI = 2.06–8.13; p < 0.0001). The multiple logistic regression analysis showed that IO was significantly associated with CC homozygosis in the SNP − 174 G>C gene promoter of IL-6 (OR = 6.3, 95% CI = 1.9–21.4; p < 0.005) in a model adjusted by age and body mass index. In conclusion, CC homozygosis in the SNP − 174 G>C gene promoter of IL-6 can be proposed as one of the gene variants influencing iron accumulation in male adults with HFE mutations. Studies in larger cohorts are warranted.
Literature
1.
go back to reference Piperno A (1998) Classification and diagnosis of iron overload. Haematologica 83(5):447–455PubMed Piperno A (1998) Classification and diagnosis of iron overload. Haematologica 83(5):447–455PubMed
2.
3.
go back to reference Pietrangelo A, Caleffi A, Corradini E (2011) Non-HFE hepatic iron overload. Semin Liver Dis 31(3):302–318CrossRefPubMed Pietrangelo A, Caleffi A, Corradini E (2011) Non-HFE hepatic iron overload. Semin Liver Dis 31(3):302–318CrossRefPubMed
4.
go back to reference Swinkels DW, Janssen MC, Bergmans J, Marx JJ (2006) Hereditary hemochromatosis: genetic complexity and new diagnostic approaches. Clin Chem 52(6):950–968CrossRefPubMed Swinkels DW, Janssen MC, Bergmans J, Marx JJ (2006) Hereditary hemochromatosis: genetic complexity and new diagnostic approaches. Clin Chem 52(6):950–968CrossRefPubMed
6.
go back to reference Pietrangelo A (2010) Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology 139(2):393–408 e1–2CrossRefPubMed Pietrangelo A (2010) Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology 139(2):393–408 e1–2CrossRefPubMed
7.
go back to reference Altes Hernandez A, Aranalde Forto J (2009) Role of hepcidin in the pathogenesis of hemochromatosis. Gastroenterol Hepatol 32(9):622–626CrossRefPubMed Altes Hernandez A, Aranalde Forto J (2009) Role of hepcidin in the pathogenesis of hemochromatosis. Gastroenterol Hepatol 32(9):622–626CrossRefPubMed
8.
go back to reference Beutler E, Waalen J, Gelbart T (2005) Chronic inflammation does not appear to modify the homozygous hereditary hemochromatosis phenotype. Blood Cells Mol Dis 35(3):326–327CrossRefPubMed Beutler E, Waalen J, Gelbart T (2005) Chronic inflammation does not appear to modify the homozygous hereditary hemochromatosis phenotype. Blood Cells Mol Dis 35(3):326–327CrossRefPubMed
9.
go back to reference Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P (1998) The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102(7):1369–1376CrossRefPubMedPubMedCentral Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P (1998) The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102(7):1369–1376CrossRefPubMedPubMedCentral
10.
go back to reference Maedler K, Dharmadhikari G, Schumann DM et al (2011) Interleukin-targeted therapy for metabolic syndrome and type 2 diabetes. Handb Exp Pharmacol 203:257–278CrossRef Maedler K, Dharmadhikari G, Schumann DM et al (2011) Interleukin-targeted therapy for metabolic syndrome and type 2 diabetes. Handb Exp Pharmacol 203:257–278CrossRef
12.
go back to reference Riikola A, Sipila K, Kahonen M et al (2009) Interleukin-6 promoter polymorphism and cardiovascular risk factors: the Health 2000 Survey. Atherosclerosis 207(2):466–470CrossRefPubMed Riikola A, Sipila K, Kahonen M et al (2009) Interleukin-6 promoter polymorphism and cardiovascular risk factors: the Health 2000 Survey. Atherosclerosis 207(2):466–470CrossRefPubMed
13.
go back to reference Fernandez-Real JM, Broch M, Vendrell J, Gutierrez C, Casamitjana R, Pugeat M, Richart C, Ricart W (2000) Interleukin-6 gene polymorphism and insulin sensitivity. Diabetes 49(3):517–520CrossRefPubMed Fernandez-Real JM, Broch M, Vendrell J, Gutierrez C, Casamitjana R, Pugeat M, Richart C, Ricart W (2000) Interleukin-6 gene polymorphism and insulin sensitivity. Diabetes 49(3):517–520CrossRefPubMed
15.
go back to reference (2017) Standards of Medical Care in Diabetes—2017 Abridged for Primary Care Providers. Clin Diabetes 35(1):5–26 (2017) Standards of Medical Care in Diabetes—2017 Abridged for Primary Care Providers. Clin Diabetes 35(1):5–26
17.
go back to reference Muller-Steinhardt M, Schulte F, Kluter H et al (2009) Optimized PCR with sequence specific primers (PCR-SSP) for fast and efficient determination of Interleukin-6 Promoter -597/-572/-174Haplotypes. BMC Res Notes 2:245CrossRefPubMedPubMedCentral Muller-Steinhardt M, Schulte F, Kluter H et al (2009) Optimized PCR with sequence specific primers (PCR-SSP) for fast and efficient determination of Interleukin-6 Promoter -597/-572/-174Haplotypes. BMC Res Notes 2:245CrossRefPubMedPubMedCentral
18.
go back to reference Rey J, Castro M, Lardo MM et al (2011) Análisis de las mutaciones del gen HFE relacionadas a hemocromatosis hereditaria en varones del área metropolitana de Buenos Aires. Implicancias en relación con características de la dieta habitual. Bioquímica y Patología Cliníca 75(3):13–17 Rey J, Castro M, Lardo MM et al (2011) Análisis de las mutaciones del gen HFE relacionadas a hemocromatosis hereditaria en varones del área metropolitana de Buenos Aires. Implicancias en relación con características de la dieta habitual. Bioquímica y Patología Cliníca 75(3):13–17
19.
go back to reference Patel DN, King CA, Bailey SR, Holt JW, Venkatachalam K, Agrawal A, Valente AJ, Chandrasekar B (2007) Interleukin-17 stimulates C-reactive protein expression in hepatocytes and smooth muscle cells via p38 MAPK and ERK1/2-dependent NF-kappaB and C/EBPbeta activation. J Biol Chem 282(37):27229–27238CrossRefPubMed Patel DN, King CA, Bailey SR, Holt JW, Venkatachalam K, Agrawal A, Valente AJ, Chandrasekar B (2007) Interleukin-17 stimulates C-reactive protein expression in hepatocytes and smooth muscle cells via p38 MAPK and ERK1/2-dependent NF-kappaB and C/EBPbeta activation. J Biol Chem 282(37):27229–27238CrossRefPubMed
20.
go back to reference Pandolfi JB, Ferraro AA, Sananez I, Gancedo MC, Baz P, Billordo LA, Fainboim L, Arruvito L (2016) ATP-induced inflammation drives tissue-resident Th17 cells in metabolically unhealthy obesity. J Immunol 196(8):3287–3296CrossRefPubMed Pandolfi JB, Ferraro AA, Sananez I, Gancedo MC, Baz P, Billordo LA, Fainboim L, Arruvito L (2016) ATP-induced inflammation drives tissue-resident Th17 cells in metabolically unhealthy obesity. J Immunol 196(8):3287–3296CrossRefPubMed
21.
go back to reference Merono T, Gomez L, Sorroche P et al (2011) High risk of cardiovascular disease in iron overload patients. Eur J Clin Investig 41(5):479–486CrossRef Merono T, Gomez L, Sorroche P et al (2011) High risk of cardiovascular disease in iron overload patients. Eur J Clin Investig 41(5):479–486CrossRef
22.
go back to reference Merono T, Brites F, Dauteuille C et al (2015) Metabolic alterations, HFE gene mutations and atherogenic lipoprotein modifications in patients with primary iron overload. Clin Sci (Lond) 128(9):609–618CrossRef Merono T, Brites F, Dauteuille C et al (2015) Metabolic alterations, HFE gene mutations and atherogenic lipoprotein modifications in patients with primary iron overload. Clin Sci (Lond) 128(9):609–618CrossRef
23.
go back to reference Solanas-Barca M, Mateo-Gallego R, Calmarza P, Jarauta E, Bea AM, Cenarro A, Civeira F (2009) Mutations in HFE causing hemochromatosis are associated with primary hypertriglyceridemia. J Clin Endocrinol Metab 94(11):4391–4397CrossRefPubMed Solanas-Barca M, Mateo-Gallego R, Calmarza P, Jarauta E, Bea AM, Cenarro A, Civeira F (2009) Mutations in HFE causing hemochromatosis are associated with primary hypertriglyceridemia. J Clin Endocrinol Metab 94(11):4391–4397CrossRefPubMed
Metadata
Title
− 174 G>C IL-6 polymorphism and primary iron overload in male patients
Authors
Walter F. Tetzlaff
Tomás Meroño
Eliana E. Botta
Maximiliano E. Martín
Patricia B. Sorroche
Laura E. Boero
Marcelo Castro
Gustavo D. Frechtel
Jorge Rey
Jorge Daruich
Gloria E. Cerrone
Fernando Brites
Publication date
01-09-2018
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 9/2018
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-018-3333-6

Other articles of this Issue 9/2018

Annals of Hematology 9/2018 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.